2022-02-01 2023-01-31 false Capium Accounts Production 1.1 07498428 bus:AbridgedAccounts 2022-02-01 2023-01-31 07498428 bus:FRS102 2022-02-01 2023-01-31 07498428 bus:AuditExempt-NoAccountantsReport 2022-02-01 2023-01-31 07498428 bus:SmallCompaniesRegimeForAccounts 2022-02-01 2023-01-31 07498428 bus:PrivateLimitedCompanyLtd 2022-02-01 2023-01-31 07498428 2022-02-01 2023-01-31 07498428 2023-01-31 07498428 bus:RegisteredOffice 2022-02-01 2023-01-31 07498428 core:WithinOneYear 2023-01-31 07498428 core:AfterOneYear 2023-01-31 07498428 bus:Director1 2022-02-01 2023-01-31 07498428 bus:Director1 2023-01-31 07498428 bus:Director1 2021-02-01 2022-01-31 07498428 bus:Director2 2022-02-01 2023-01-31 07498428 bus:Director2 2023-01-31 07498428 bus:Director2 2021-02-01 2022-01-31 07498428 2021-02-01 07498428 bus:CompanySecretary1 2022-02-01 2023-01-31 07498428 bus:LeadAgentIfApplicable 2022-02-01 2023-01-31 07498428 2021-02-01 2022-01-31 07498428 2022-01-31 07498428 core:WithinOneYear 2022-01-31 07498428 core:AfterOneYear 2022-01-31 07498428 bus:EntityAccountantsOrAuditors 2021-02-01 2022-01-31 07498428 bus:OrdinaryShareClass1 2022-02-01 2023-01-31 07498428 bus:OrdinaryShareClass1 2023-01-31 07498428 bus:OrdinaryShareClass1 2021-02-01 2022-01-31 07498428 bus:OrdinaryShareClass1 2022-01-31 07498428 core:CostValuation core:Non-currentFinancialInstruments 2023-01-31 07498428 core:CostValuation core:Non-currentFinancialInstruments 2022-01-31 07498428 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-01-31 07498428 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2023-01-31 07498428 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2023-01-31 07498428 core:Non-currentFinancialInstruments 2023-01-31 07498428 core:Non-currentFinancialInstruments 2022-01-31 07498428 core:ShareCapital 2023-01-31 07498428 core:ShareCapital 2022-01-31 07498428 core:RetainedEarningsAccumulatedLosses 2023-01-31 07498428 core:RetainedEarningsAccumulatedLosses 2022-01-31 07498428 dpl:Item1 2022-02-01 07498428 dpl:Item1 2023-01-31 07498428 dpl:Item1 2021-02-01 07498428 dpl:Item1 2022-01-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 07498428
England and Wales

 

 

 

REVA CLINICAL CONSULTANTS LIMITED


Abridged Accounts
 


Period of accounts

Start date: 01 February 2022

End date: 31 January 2023
 
 
Notes
 
2023
£
  2022
£
Fixed assets      
Investments 3 41,000    30,000 
41,000    30,000 
Current assets      
Debtors: amounts falling due within one year 9,900   
Cash at bank and in hand 19,871    94,985 
29,771    94,985 
Creditors: amount falling due within one year (55,949)   (87,735)
Net current liabilities (26,178)   7,250 
 
Total assets less current liabilities 14,822    37,250 
Net assets 14,822    37,250 
 

Capital and reserves
     
Called up share capital 4 2    2 
Profit and loss account 14,820    37,248 
Shareholder's funds 14,822    37,250 
 


For the year ended 31 January 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of Part 15 of the Companies Act 2006. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the board of directors on 16 November 2023 and were signed on its behalf by:


-------------------------------
Mr Hemant Arora
Director
1
General Information
Reva Clinical Consultants Limited is a private company, limited by shares, registered in England and Wales, registration number 07498428, registration address 14 Yarmouth Close , Crawley, West Sussex , RH10 6TH.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Fixed asset investments
Fixed asset investments are stated at cost less provision for any permanent diminution in value.
2.

Average number of employees

Average number of employees during the year was 2 (2022 : 2).
3.

Investments

Cost Other investments other than loans   Total
  £   £
At 01 February 2022 30,000    30,000 
Additions 11,000    11,000 
Transfer to/from tangible fixed assets  
Disposals  
At 31 January 2023 41,000    41,000 

4.

Share Capital

Allotted, called up and fully paid
2023
£
  2022
£
2 Class A shares of £1.00 each  
 

2